ACLARIS THERAPEUTICS INC (ACRS) Stock Analyst Earnings Estimates
NASDAQ:ACRS - Nasdaq - US00461U1051 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.76M 4.32% | 29.75M 340.09% | 31.249M 5.04% | 11.842M -62.10% | 9.107M -23.10% | 7.583M -16.73% | 11.417M 50.56% | 42.905M 275.80% | 172.46M 301.96% | 402.31M 133.28% | 65.28M -83.77% | 98.94M 51.56% | |
| EBITDA YoY % growth | -64.46M -29.99% | -84.35M -30.86% | -88.551M -4.98% | -93.23M -5.28% | -78.452M 15.85% | -83.36M -6.26% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -65.38M -28.42% | -85.15M -30.24% | -89.414M -5.01% | -62.263M 30.37% | -65.826M -5.72% | -87.198M -32.47% | -78.545M 9.92% | -56.168M 28.49% | 66.646M 218.66% | 269.52M 304.41% | -47.94M -117.79% | -31.62M 34.04% | |
| Operating Margin | -967.16% | -286.22% | -286.13% | -525.78% | -722.81% | -1,149.92% | -687.97% | -130.91% | 38.64% | 66.99% | -73.44% | -31.96% | |
| EPS YoY % growth | -1.63 -35.83% | -1.33 18.40% | -1.25 6.02% | -0.75 40.40% | -0.56 24.31% | -0.70 -23.72% | -0.82 -17.69% | -1.00 -21.74% | -0.83 17.35% | 0.29 134.57% | 0.82 185.71% | 1.72 111.25% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 -1,014.71% | -0.12 49.85% | -0.14 4.80% | -0.15 -39.09% | -0.16 27.71% | -0.13 -10.17% | -0.13 7.14% | -0.12 20.00% | -0.12 24.05% |
| Revenue Q2Q % growth | 2.15M -87.76% | 3.226M 34.53% | 1.543M -44.22% | 1.594M -63.32% | 1.619M -24.70% | 663K -79.45% | 663K -57.03% | 663K -58.41% | 663K -59.05% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -23.516M -1,010.78% | -15.142M 20.01% | -16.366M -27.32% | -17.59M -67.99% | -18.44M 21.59% | -18.601M -22.84% | -19.264M -17.70% | -19.825M -12.70% | -20.896M -13.32% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.11 73.17% | -0.01 | -0.10 | -1,788.67% |
| Q2 2024 Q2Q % growth | -0.15 64.29% | -0.21 | 0.06 | 28.07% |
| Q1 2024 Q2Q % growth | -0.24 40.00% | -0.29 | 0.05 | 17.65% |
| Q4 2023 Q2Q % growth | -0.02 95.12% | -0.35 | 0.33 | 94.31% |
| Q3 2023 Q2Q % growth | -0.41 -36.67% | -0.49 | 0.08 | 16.26% |
| Q2 2023 Q2Q % growth | -0.42 -35.48% | -0.46 | 0.04 | 8.50% |
| Q1 2023 Q2Q % growth | -0.40 -29.03% | -0.45 | 0.05 | 10.42% |
| Q4 2022 Q2Q % growth | -0.41 -10.81% | -0.45 | 0.04 | 9.79% |
| Q3 2022 Q2Q % growth | -0.30 14.29% | -0.40 | 0.10 | 25.67% |
| Q2 2022 Q2Q % growth | -0.31 8.82% | -0.37 | 0.06 | 15.18% |
| Q1 2022 Q2Q % growth | -0.31 45.61% | -0.41 | 0.10 | 24.65% |
| Q4 2021 Q2Q % growth | -0.37 -23.33% | -0.37 | 0.00 | 0.62% |
| Q3 2021 Q2Q % growth | -0.35 -40.00% | -0.29 | -0.06 | -22.55% |
| Q2 2021 Q2Q % growth | -0.34 -21.43% | -0.28 | -0.06 | -20.48% |
| Q1 2021 Q2Q % growth | -0.57 -54.05% | -0.29 | -0.28 | -94.37% |
| Q4 2020 Q2Q % growth | -0.30 33.33% | -0.27 | -0.03 | -10.29% |
| Q3 2020 Q2Q % growth | -0.25 81.34% | -0.31 | 0.06 | 19.20% |
| Q2 2020 Q2Q % growth | -0.28 63.16% | -0.37 | 0.09 | 23.75% |
| Q1 2020 Q2Q % growth | -0.37 59.34% | -0.33 | -0.04 | -11.61% |
| Q4 2019 Q2Q % growth | -0.45 | -0.40 | -0.05 | -11.69% |
| Q3 2019 Q2Q % growth | -1.34 | -0.58 | -0.76 | -131.83% |
| Q2 2019 Q2Q % growth | -0.76 | -0.77 | 0.01 | 1.64% |
| Q1 2019 Q2Q % growth | -0.91 | -0.82 | -0.09 | -11.17% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 4.346M -53.18% | 7.262M | -2.916M | -40.15% |
| Q2 2024 Q2Q % growth | 2.766M 47.99% | 1.854M | 912K | 49.19% |
| Q1 2024 Q2Q % growth | 2.398M -5.14% | 1.394M | 1.004M | 72.02% |
| Q4 2023 Q2Q % growth | 17.57M 126.71% | 3.431M | 14.139M | 412.10% |
| Q3 2023 Q2Q % growth | 9.282M -51.20% | 1.605M | 7.677M | 478.32% |
| Q2 2023 Q2Q % growth | 1.869M 22.16% | 1.937M | -68K | -3.51% |
| Q1 2023 Q2Q % growth | 2.528M 74.34% | 1.783M | 745K | 41.78% |
| Q4 2022 Q2Q % growth | 7.75M 416.67% | 2.034M | 5.716M | 281.02% |
| Q3 2022 Q2Q % growth | 19.02M 1,045.78% | 1.637M | 17.383M | 1,061.88% |
| Q2 2022 Q2Q % growth | 1.53M -15.93% | 1.644M | -114K | -6.93% |
| Q1 2022 Q2Q % growth | 1.45M -18.54% | 1.698M | -248K | -14.61% |
| Q4 2021 Q2Q % growth | 1.5M -5.06% | 1.827M | -327K | -17.90% |
| Q3 2021 Q2Q % growth | 1.66M 14.48% | 1.806M | -146K | -8.08% |
| Q2 2021 Q2Q % growth | 1.82M -11.22% | 1.781M | 39K | 2.19% |
| Q1 2021 Q2Q % growth | 1.78M 26.24% | 1.512M | 268K | 17.72% |
| Q4 2020 Q2Q % growth | 1.58M 43.64% | 1.418M | 162K | 11.42% |
| Q3 2020 Q2Q % growth | 1.45M 47.96% | 1.499M | -49K | -3.27% |
| Q2 2020 Q2Q % growth | 2.05M 130.34% | 1.259M | 791K | 62.83% |
| Q1 2020 Q2Q % growth | 1.41M 11.90% | 1.152M | 258K | 22.40% |
| Q4 2019 Q2Q % growth | 1.1M | 3.23M | -2.13M | -65.94% |
| Q3 2019 Q2Q % growth | 980K | 5.939M | -4.959M | -83.50% |
| Q2 2019 Q2Q % growth | 890K | 5.657M | -4.767M | -84.27% |
| Q1 2019 Q2Q % growth | 1.26M | 4.909M | -3.649M | -74.33% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -29.66% | -0.59% | -7.87% |
| Revenue | 0% | -2.09% | 0% | -0.39% |